The Effect of Food on the Absorption of Oral Ziprasidone
The Effect of Food on the Absorption of Oral Ziprasidone By Jeffrey J.Miceli, PhD, Paul Glue, MD, PhD, Jeffrey Alderman, PhD, and Keith Wilner, PhD
$5 Insanity: A New Drug of Abuse
What is this new insanity drug of abuse known as gravel or flakka? Recent news reports detail a man, who thought he was being chased by dozens of cars, using every ounce of strength to break the glass of a police station entrance door. Another man ran naked down the [...]
Rexulti now in pharmacies, a new treatment for schizophrenia and MDD
Rexulti: New treatment for schizophrenia and major depressive disorder approved and released by FDA On July 10, the U.S. Food and Drug Administration approved Rexulti (brexpiprazole) tablets to treat adults with schizophrenia and as an add-on treatment to an antidepressant medication to treat adults with major depressive disorder (MDD). [...]
Submission, Volume 42, Number 4
The Efficacy and Tolerability of Once-daily Controlled-release Trazodone for Depressed Mood, Anxiety, Insomnia, and Suicidality in Major Depressive Disorder By David V. Sheehan, MD, MBA; Anna Rozova, MSc, MD; E. Roderich Gossen, PhD; Michael Gibertini, PhD Abstract Trazodone Contramid® once-a-day (TzCOAD) is a reformulation of trazodone hydrochloride that controls the [...]
ABSTRACTS, VOLUME 42, NUMBER 1
Psychopharmacology BULLETIN Newsletter the advance newsletter of Psychopharmacology BULLETIN Summary—Index of This Issue On-Press ORIGINAL RESEARCH EVIDENCE-BASED MEDICINEORIGINAL RESEARCH: The Trials and Travails Atypical Antipsychotic Drugs and Diabetes in the US Adverse Event Database Bipolar-I Patient Characteristics PTSD Following Short-Term Paroxetine Treatment Aripiprazole in the Treatment of PTSD Memantine: An [...]
Psychopharmacology Bulletin Newsletter 4
• ORIGINAL RESEARCH • EVIDENCE BASED MEDICINE • GENERAL PSYCHIATRY Seroquel Once a Day: A Randomized, Double-Blind, Placebo-Controlled Study— This 6-week, randomized, double-blind study aimed to demonstrate efficacy of once-daily extended release quetiapine fumarate (quetiapine XR) versus placebo in patients with acute schizophrenia resulting in the efficacy of quetiapine XR [...]
Psychopharmacology Bulletin Newsletter 3
Newsletter No. 3, 2008 www.psychopharmbulletin.com Volume 41 • Number 3 • 2008 Psychopharmacology BULLETIN Newsletter the advance newsletter of Psychopharmacology BULLETIN Summary—Index of This Issue On-Press ORIGINAL RESEARCH EVIDENCE BASED MEDICINE Cocaine is a Major Risk Factor for Antipsychotic Induced Akathisia, Parkinsonism and Dyskinesia abstract ~ Objective: To assess [...]
Psychopharmacology Bulletin Newsletter 2
Newsletter No. 2, 2008 www.psychopharmbulletin.com Volume 41 • Number 2 • 2008 Psychopharmacology BULLETIN Newsletter the advance newsletter of Psychopharmacology BULLETIN Summary—Index of This Issue On-Press • ORIGINAL RESEARCH • EVIDENCE BASED MEDICINE Are SNRIs More Effective than SSRIs? A Review of the Current State of the Controversy—p.2 [...]
Psychopharmacology Bulletin Newsletter 1
• ORIGINAL RESEARCH • EVIDENCE BASED MEDICINE ORIGINAL RESEARCH: The Trials and Travails Placebo-Controlled — PTSD Double-Blind — ADHD Pilot-Controlled — GAD Comparative Analysis — ANTIDEPRESSANT TRIALS A Placebo-Controlled Trial of Guanfacine for the Treatment of PTSD in Veterans —p.2 Lori Davis, MD, L. Charles Ward, PhD, Ann Rasmusson, MD, [...]
Evidence-Based Medicine
Psychiatry in the Postgenomic Era Kathy L. Kopnisky, PhD Steven E. Hyman, MD Dr. Kopnisky is assistant to the director, and Dr. Hyman is director, both at the National Institute of Mental Health in Bethesda, MD. Abstract A rough draft of the human genome sequence is now available in the [...]